Shilpa Malakar, Emmanuel Nuah Gontor, Moses Y. Dugbaye, Kamal Shah, Sakshi Sinha, Priya Sutaoney, Nagendra Singh Chauhan
{"title":"使用生物类似药治疗癌症:综述","authors":"Shilpa Malakar, Emmanuel Nuah Gontor, Moses Y. Dugbaye, Kamal Shah, Sakshi Sinha, Priya Sutaoney, Nagendra Singh Chauhan","doi":"10.1002/cai2.115","DOIUrl":null,"url":null,"abstract":"<p>Biosimilars are biological drugs created from living organisms or that contain living components. They share an identical amino-acid sequence and immunogenicity. These drugs are considered to be cost-effective and are utilized in the treatment of cancer and other endocrine disorders. The primary aim of biosimilars is to predict biosimilarity, efficacy, and treatment costs; they are approved by the Food and Drug Administration (FDA) and have no clinical implications. They involve analytical studies to understand the similarities and dissimilarities. A biosimilar manufacturer sets up FDA-approved reference products to evaluate biosimilarity. The contribution of next-generation sequencing is evolving to study the organ tumor and its progression with its impactful therapeutic approach on cancer patients to showcase and target rare mutations. The study shall help to understand the future perspectives of biosimilars for use in gastro-entero-logic diseases, colorectal cancer, and thyroid cancer. They also help target specific organs with essential mutational categories and drug prototypes in clinical practices with blood and liquid biopsy, cell treatment, gene therapy, recombinant therapeutic proteins, and personalized medications. Biosimilar derivatives such as monoclonal antibodies like trastuzumab and rituximab are common drugs used in cancer therapy. <i>Escherichia coli</i> produces more than six antibodies or antibody-derived proteins to treat cancer such as filgrastim, epoetin alfa, and so on.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"3 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.115","citationCount":"0","resultStr":"{\"title\":\"Cancer treatment with biosimilar drugs: A review\",\"authors\":\"Shilpa Malakar, Emmanuel Nuah Gontor, Moses Y. Dugbaye, Kamal Shah, Sakshi Sinha, Priya Sutaoney, Nagendra Singh Chauhan\",\"doi\":\"10.1002/cai2.115\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Biosimilars are biological drugs created from living organisms or that contain living components. They share an identical amino-acid sequence and immunogenicity. These drugs are considered to be cost-effective and are utilized in the treatment of cancer and other endocrine disorders. The primary aim of biosimilars is to predict biosimilarity, efficacy, and treatment costs; they are approved by the Food and Drug Administration (FDA) and have no clinical implications. They involve analytical studies to understand the similarities and dissimilarities. A biosimilar manufacturer sets up FDA-approved reference products to evaluate biosimilarity. The contribution of next-generation sequencing is evolving to study the organ tumor and its progression with its impactful therapeutic approach on cancer patients to showcase and target rare mutations. The study shall help to understand the future perspectives of biosimilars for use in gastro-entero-logic diseases, colorectal cancer, and thyroid cancer. They also help target specific organs with essential mutational categories and drug prototypes in clinical practices with blood and liquid biopsy, cell treatment, gene therapy, recombinant therapeutic proteins, and personalized medications. Biosimilar derivatives such as monoclonal antibodies like trastuzumab and rituximab are common drugs used in cancer therapy. <i>Escherichia coli</i> produces more than six antibodies or antibody-derived proteins to treat cancer such as filgrastim, epoetin alfa, and so on.</p>\",\"PeriodicalId\":100212,\"journal\":{\"name\":\"Cancer Innovation\",\"volume\":\"3 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.115\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Innovation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cai2.115\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Innovation","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cai2.115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
生物仿制药是指从生物体中提取或含有生物成分的生物药物。它们具有相同的氨基酸序列和免疫原性。这些药物被认为具有成本效益,可用于治疗癌症和其他内分泌疾病。生物仿制药的主要目的是预测生物相似性、疗效和治疗成本;它们由美国食品和药物管理局(FDA)批准,对临床没有影响。它们涉及分析研究,以了解相似性和不相似性。生物仿制药生产商会建立经 FDA 批准的参照产品,以评估生物仿制药的相似性。下一代测序技术在研究器官肿瘤及其进展方面的贡献正在不断发展,其对癌症患者的影响治疗方法可展示并锁定罕见突变。这项研究将有助于了解生物仿制药在胃肠道疾病、结直肠癌和甲状腺癌中的应用前景。生物仿制药还有助于在临床实践中通过血液和液体活检、细胞治疗、基因治疗、重组治疗蛋白和个性化药物,针对特定器官的基本突变类别和药物原型进行治疗。生物仿制药的衍生物,如曲妥珠单抗和利妥昔单抗等单克隆抗体,是癌症治疗中常用的药物。大肠杆菌可产生六种以上治疗癌症的抗体或抗体衍生蛋白,如 filgrastim、epoetin alfa 等。
Biosimilars are biological drugs created from living organisms or that contain living components. They share an identical amino-acid sequence and immunogenicity. These drugs are considered to be cost-effective and are utilized in the treatment of cancer and other endocrine disorders. The primary aim of biosimilars is to predict biosimilarity, efficacy, and treatment costs; they are approved by the Food and Drug Administration (FDA) and have no clinical implications. They involve analytical studies to understand the similarities and dissimilarities. A biosimilar manufacturer sets up FDA-approved reference products to evaluate biosimilarity. The contribution of next-generation sequencing is evolving to study the organ tumor and its progression with its impactful therapeutic approach on cancer patients to showcase and target rare mutations. The study shall help to understand the future perspectives of biosimilars for use in gastro-entero-logic diseases, colorectal cancer, and thyroid cancer. They also help target specific organs with essential mutational categories and drug prototypes in clinical practices with blood and liquid biopsy, cell treatment, gene therapy, recombinant therapeutic proteins, and personalized medications. Biosimilar derivatives such as monoclonal antibodies like trastuzumab and rituximab are common drugs used in cancer therapy. Escherichia coli produces more than six antibodies or antibody-derived proteins to treat cancer such as filgrastim, epoetin alfa, and so on.